{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:34:18Z","timestamp":1791326058263,"version":"4.3.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virus Eradication"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jve.2024.100365","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T17:34:48Z","timestamp":1709746488000},"page":"100365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Study on immune persistence of the CTN-1V strain rabies vaccine in humans"],"prefix":"10.1016","volume":"10","author":[{"given":"Lidong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyue","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danhua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Li Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jve.2024.100365_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003786","article-title":"Estimating the global burden of endemic canine rabies","volume":"9","author":"Hampson","year":"2015","journal-title":"PLoS Neglected Trop Dis"},{"issue":"2","key":"10.1016\/j.jve.2024.100365_bib2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0264-410X(89)90050-9","article-title":"Comparative study of the safety and protective value, in pre-exposure use, of rabies vaccine cultivated on human diploid cells (HDCV) and of the new vaccine grown on Vero cells","volume":"7","author":"Ajjan","year":"1989","journal-title":"Vaccine"},{"issue":"77","key":"10.1016\/j.jve.2024.100365_bib3","first-page":"109","article-title":"Rabies vaccines: WHO position paper","volume":"14","author":"World Health Organization","year":"2002","journal-title":"Wkly Epidemiol Rec"},{"issue":"82","key":"10.1016\/j.jve.2024.100365_bib4","first-page":"425","article-title":"Rabies vaccines: WHO position paper, April 2018 - recommendations","volume":"No. 49\/50","author":"World Health Organization","year":"2007","journal-title":"Wkly Epidemiol Rec"},{"issue":"16","key":"10.1016\/j.jve.2024.100365_bib5","first-page":"201","article-title":"Rabies vaccines: WHO position paper, April 2018 - recommendations","volume":"93","author":"World Health Organization","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.jve.2024.100365_bib6","first-page":"95","volume":"vol. 41","author":"World Health Organization","year":"2007"},{"issue":"11","key":"10.1016\/j.jve.2024.100365_bib7","first-page":"1375","article-title":"Application and research progress of Rabies virus CTN-1 strain in human Rabies vaccine","volume":"34","author":"Shi","year":"2021","journal-title":"Chinese Journal of Biological Products"},{"issue":"2","key":"10.1016\/j.jve.2024.100365_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.biologicals.2009.01.001","article-title":"The rapid fluorescent focus inhibition test is a suitable method for batch potency testing of inactivated rabies vaccines","volume":"37","author":"Kr\u00e4mer","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.jve.2024.100365_bib9","series-title":"Laboratory Techniques in Rabies","first-page":"196","author":"Rupprecht","year":"2018"},{"issue":"8","key":"10.1016\/j.jve.2024.100365_bib10","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1080\/21645515.2021.1880200","article-title":"Safety, immunogenicity of lyophilized purified Vero cell cultured rabies vaccine administered in Zagreb and Essen regimen in post-exposure subjects: a post-marketing, parallel control clinical trial","volume":"17","author":"Zhang","year":"2021","journal-title":"Hum Vaccines Immunother"},{"issue":"1","key":"10.1016\/j.jve.2024.100365_bib11","first-page":"74","article-title":"Immune persistence of human Rabies vaccine (Vero cell) basic immunization and immunogenicity and safety of booster immunization after exposure to 18-50 years old people","volume":"28","author":"Huang","year":"2022","journal-title":"Chin Vac Immun"},{"issue":"6","key":"10.1016\/j.jve.2024.100365_bib12","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2138049","article-title":"A simulated, randomized study on the safety and immunogenicity of three consecutive commercial-scale batches of the CTN-1V strain human rabies vaccine to verify the inter-batch consistency","volume":"18","author":"Zhou","year":"2022","journal-title":"Hum Vaccines Immunother"},{"issue":"32","key":"10.1016\/j.jve.2024.100365_bib13","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1016\/S0264-410X(01)00238-9","article-title":"Immunogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized, double-blind trial with human diploid cell rabies vaccine","volume":"19","author":"Jones","year":"2001","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.jve.2024.100365_bib14","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1080\/21645515.2017.1279770","article-title":"Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects","volume":"13","author":"Shi","year":"2017","journal-title":"Hum Vaccines Immunother"},{"issue":"2","key":"10.1016\/j.jve.2024.100365_bib15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.4161\/21645515.2014.994460","article-title":"Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study","volume":"11","author":"Li","year":"2015","journal-title":"Hum Vaccines Immunother"},{"issue":"2","key":"10.1016\/j.jve.2024.100365_bib16","first-page":"185","article-title":"Immunogenicity and safety of WHO-approved TRC-ID regimen with a chromatographically purified Vero cell rabies vaccine with or without rabies immunoglobulin in children","volume":"17","author":"Angsuwatcharakon","year":"2018","journal-title":"Expet Rev Vaccine"},{"issue":"24","key":"10.1016\/j.jve.2024.100365_bib17","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.vaccine.2013.03.050","article-title":"Safety and immunogenicity of a new purified Vero cell rabies vaccine (PVRV) administered by intramuscular and intradermal routes in healthy volunteers","volume":"31","author":"Kulkarni","year":"2013","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.jve.2024.100365_bib18","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.4161\/21645515.2014.972773","article-title":"A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults","volume":"10","author":"Ma","year":"2014","journal-title":"Hum Vaccines Immunother"},{"issue":"2","key":"10.1016\/j.jve.2024.100365_bib19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/21645515.2020.1778408","article-title":"Immunogenicity and safety of purified Vero cell-cultured rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in the healthy Chinese subjects: a randomized, double-blind, positive controlled phase 3 clinical trial","volume":"17","author":"Shen","year":"2021","journal-title":"Hum Vaccines Immunother"},{"issue":"40","key":"10.1016\/j.jve.2024.100365_bib20","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1016\/j.vaccine.2016.08.005","article-title":"A randomized non-inferiority clinical study to assess post-exposure prophylaxis by a new purified Vero cell rabies vaccine (Rabivax-S) administered by intramuscular and intradermal routes","volume":"34","author":"Bose","year":"2016","journal-title":"Vaccine"}],"container-title":["Journal of Virus Eradication"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2055664024000025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2055664024000025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T22:37:02Z","timestamp":1731537422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2055664024000025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2055664024000025"],"URL":"https:\/\/doi.org\/10.1016\/j.jve.2024.100365","relation":{},"ISSN":["2055-6640"],"issn-type":[{"value":"2055-6640","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study on immune persistence of the CTN-1V strain rabies vaccine in humans","name":"articletitle","label":"Article Title"},{"value":"Journal of Virus Eradication","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jve.2024.100365","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100365"}}